Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraceptive efficacy

J Trussell

    Archives of Dermatology
    |September 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Contraceptive efficacy is crucial for women using teratogenic drugs like isotretinoin. Understanding factors influencing birth control effectiveness helps patients and clinicians make informed decisions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response to "study of contraceptive mobile app fails to provide convincing findings".

    Contraception·2018
    Same author

    Clarifications concerning contraceptive mobile app Pearl Index calculations.

    Contraception·2018
    Same author

    Perfect-use and typical-use Pearl Index of a contraceptive mobile app.

    Contraception·2017
    Same author

    Contraceptive method preferences and provision after termination of pregnancy: a population-based analysis of women obtaining care with the British Pregnancy Advisory Service.

    BJOG : an international journal of obstetrics and gynaecology·2016
    Same author

    Experiences and characteristics of women seeking and completing at-home medical termination of pregnancy through online telemedicine in Ireland and Northern Ireland: a population-based analysis.

    BJOG : an international journal of obstetrics and gynaecology·2016
    Same author

    In the midst of Zika pregnancy advisories, termination of pregnancy is the elephant in the room.

    BJOG : an international journal of obstetrics and gynaecology·2016
    Same journal

    Scoring With SCORTEN-Reply.

    Archives of dermatology·2017
    Same journal

    Comparison of Early and Late Latent Syphilis- Colorado, 1991.

    Archives of dermatology·2016
    Same journal

    Case of Rhinoscleroma.

    Archives of dermatology·2016
    Same journal

    Cutaneous Fungal Infections.

    Archives of dermatology·2016
    Same journal

    An Ulcerated Plaque in a Gay Man.

    Archives of dermatology·2016
    Same journal

    Solitary Violaceous Nodule on the Face.

    Archives of dermatology·2016
    See all related articles

    Area of Science:

    • Dermatology
    • Pharmacology
    • Reproductive Health

    Background:

    • Assessing contraceptive efficacy is a primary concern for patients and clinicians, especially when using teratogenic medications.
    • Dermatologists frequently prescribe potent teratogenic drugs, including isotretinoin and thalidomide, necessitating careful consideration of birth control methods.
    • Certainty in contraceptive effectiveness cannot be guaranteed for all individuals.

    Discussion:

    • The question of "Will it work?" is paramount when discussing contraception with patients using teratogenic drugs.
    • Clinicians and counselors play a vital role in educating patients about various factors that impact contraceptive efficacy.
    • This discussion is particularly relevant for dermatologists managing patients on isotretinoin and thalidomide.

    Key Insights:

    Related Experiment Videos

    • Contraceptive efficacy is a significant concern for women using teratogenic drugs prescribed by dermatologists.
    • Isotretinoin and thalidomide are potent teratogenic drugs requiring careful management of birth control.
    • Patient counseling on factors influencing contraceptive effectiveness is essential.

    Outlook:

    • Further research into optimizing contraceptive strategies for patients using teratogenic medications is warranted.
    • Enhanced patient-provider communication regarding contraceptive risks and benefits is crucial.
    • Developing guidelines for dermatologists on managing contraception for patients on teratogenic drugs will improve patient safety.